Endometrial hyperplasia - from pathogenesis to effective therapy
AbstractEndometrial hyperplasia is increasingly attracting the close attention of doctors of various specialties: gynecologists, oncologists, morphologists, endocrinologists and others. This interest is due to both the frequency of their occurrence and the pre-cancerous disease character. The problem is even more significant due to the functional and structural changes in the reproductive system of women, which leads to a decrease in the quality of life.
The article discusses the modern ideas about etiopathogenesis and the tactics of management of patients, according to the data of foreign literature.
Keywords:endometrial hyperplasia, endometrial cancer, oral progestins, hysterectomy
Funding. The authors received no financial support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Orazov M.R., Khamoshina M.B., Mullina I.A., Artemenko Yu.S. Endometrial hyperplasia - from pathogenesis to effective therapy. Akusherstvo i ginekologiya novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2021; 9 (3): 21-8. DOI: https://doi.org/10.33029/2303-9698-2021-9-3-21-28 (in Russian)
References
1. Orazov M.R. Debating points of endometrium hyperplasia case management. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2016; 3: 46-58. (in Russian)
2. Orazov M.R., Radzinsky V.E., Arakelov S.E., Khamoshina M.B., Nosenko E.N., Dukhin A.O., et al. Risk factors of endometrial hyperplasia in women of reproductive age. Trudniy patsient [Difficult Patient]. 2019; 17 (5). (in Russian)
3. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68 (1): 7-30.
4. Caprin A.D., Starinsky V.V., Shakhzodova A.O. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow: MNIOI im. P.A. Gertsena - filial FGBU “FMITs radiologii” Minzdrava Rossii, 2020: 252 p. (in Russian)
5. Iversen M.L., Dueholm M. Complex non atypical hyperplasia and the subsequent risk of carcinoma, atypia and hysterectomy during the following 9-14 years. Eur J Obstet Gynecol Reprod Biol. 2018; 222: 171-5.
6. Dumanovskaya M.R., Chernukha G.E., Asaturova A.V., Kogan E.A. The detection rate and pattern of endometrial hyperplasia in different age periods. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2015; (3): 40-4. (in Russian)
7. Hannemann M.M., Alexander H.M., Cope N.J. Endometrial hyperplasia: a clinician's review. Obstet Gynecol Reprod Med. 2010; 20 (4): 116-20.
8. Auclair M.-H., Yong P.J., Shannon S., Thurston J., Colgan T. (Terry) J., Sebastianelli A., et al. Guideline No. 390 - Classification and Management of Endometrial Hyperplasia. J Obstet Gynaecol Can. 2019; 41 (12): 1789-800.
9. Erdem B., A§icioglu O., Seyhan N.A., Peker N., Ulker V., Akbayir O. Can concurrent high-risk endometrial carcinoma occur with atypical endometrial hyperplasia? Int J Surg. 2018; 53: 350-3.
10. Management of Endometrial Hyperplasia Green-top Guideline No. 67. RCOG/BSGE Joint Guideline. February 2016.
11. Trimble C.L., Method M., Leitao M., Lu K., Ioffe O., Hampton M., et al. Management of endometrial precancers. Obstet Gynecol. 2012; 120: 1160-75.
12. Song D., Feng X., Zhang Q., Xia E., Xiao Y., Xie W., et al. Prevalence and confounders of chronic endometritis in premenopausal women with abnormal bleeding or reproductive failure. Reprod Biomed Online. 2018; 36 (1): 78-83. DOI: https://.doi.org/10.1016/j.rbmo.2017.09.008
13. Sanderson P.A., Critchley H.O.D., Williams A.R.W., Arends M.J., Saunders P.T.K. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017; 23 (2): 232-54. DOI: https://doi.org/10.1093/humupd/dmw042
14. Suidan R.S., He W., Sun C.C., Zhao H., Fleming N.D., Ramirez P., et al. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol. 2017; 145 (1): 55-60. DOI: https://doi.org/10.1016/j.ygyno.2017.01.025
15. Mitsuhashi A., Uehara T., Hanawa S., Shozu M. Prospective evaluation of abnormal glucose metabolism and insulin resistance in patients with atypical endometrial hyperplasia and endometrial cancer. Support Care Cancer. 2017; 25 (5): 1495-501. DOI: https://doi.org/10.1007/s00520-016-3554-y
16. Wartko P.D., Beck T.L., Reed S.D., Mueller B.A., Hawes S.E. Association of endometrial hyperplasia and cancer with a history of gestational diabetes. Cancer Causes Control. 2017; 28 (8): 819-28. DOI: https://doi.org/10.1007/s10552-017-0908-9
17. Chandra V., Kim J.J., Benbrook D.M., et al. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016; 27: e8.
18. Emons G., Beckmann M.W., Schmidt D., et al. New who classification of endometrial hyperplasias. Geburtshilfe Frauenheilkd. 2015; 75: 135-6.
19. Sherman M.E., Ronnett B., Ioofe O., et al. Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification. Int J Gynecol. Pathol. 2008; 27: 318-25.
20. Wheeler D.T., Bristow R.E., Kurman R.J. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with pro-gestins. Am J Surg Pathol. 2007; 31: 988-98.
21. Dijkhuizen F.P., Mol B.W., Brolmann H.A., et al. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia. Cancer. 2000; 89: 1765-72.
22. Singh G., Puckett Y. Endometrial Hyperplasia. 2021 Apr 13. In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2021.
23. Lacey J.V. Jr, Sherman M.E., Rush B.B., et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol. 2010; 28: 788-92.
24. Reed S.D., Newton K.M., Clinton W.L., Epplein M., Garcia R., Allison K., et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009; 200: 678.e1-6.
25. Gynecology: national guidelines / ed. by G.M. Savelyeva, G.T. Sukhikh, V.N. Serov, V.E. Radzinskiy, I.B. Manukhin. Moscow: GEOTAR-Mеdia, 2020: 1008 p. (in Russian)
26. URL: https://www.rlsnet.ru/mnn_index_id_906.htm
27. Loose D.S., Stancel G.M. Estrogens and progestins. In: Brunton L.L., Lazo J.S., Parker K.L. (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006: 1541-71.
28. Instructions for the medical use of the drug Dufaston® dated 06.07.2020. (in Russian)
29. Sibirskaya E.V., Pivazyan L.G. Voprosy Hormonal therapy for management of abnormal uterine bleeding in women of late reproductive age.
Voprosy ginekologii, akusherstva i perinatologii [Problems of Gynaecology, Obstetrics and Perinatology]. 2020; 19 (2): 129-35. DOI: https://doi.org/10.20953/1726-1678-2020-2-129-135 (in Russian)
30. Podzolkova N., Tatarchuk T., Doshchanova A., Eshimbetova G., Pexman-Fieth C. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol Endocrinol. 2016; 32 (3): 246-9.
31. Griesinger G., Tournaye H., Macklon N., Petraglia F., Arck P., Blockeel C., van Amsterdam P., et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019; 38 (2): 249-59. DOI: https://doi.org/10.1016/j.rbmo.2018.11.017
32. El Behery M.M., Saleh H.S., Ibrahiem M.A., Kamal E.M., Kas-sem G.A., Mohamed Mel S. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. Reprod Sci. 2015; 22 (3): 329-34. DOI: https://doi.org/10.1177/1933719114542014
33. Kapustin R.V., Arzhanova O.N., Bespalova O.N. Exogenous progesterone as a factor for the development of gestational diabetes mellitus. Rossiyskiy vestnik akushera-ginecologa [Russian Bulletin of Obstetrician-Gynecologist]. 2019; 19 (1): 38-45. (in Russian)
34. Ulrikh E.A., Kutusheva G.F., Urmancheeva A.F. Dufaston (degidrosteron) in treatment of dysfunctional womb bleeding associated with ferrum hyperplasia of endometrium. Zhurnal akusherstva i zhenskikh bolezney [Journal of Obstetrics and Women's Diseases]. 2003; (3). (in Russian)
35. Ozolinya L.A., Lapina I.A., Boldina E.B., Lutsenko N.N. Treatment of patients with endometrial hyperplasia combined with uterine myomas. Lechebnoe delo [Medical Care]. 2011; (2): 34-39. (in Russian)
36. Solovyeva A.V., Ermolenko K.S. Differentiated approach to choosing therapy for women with abnormal uterine bleeding. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2018; (3): 157-60. (in Russian)
37. Solovyeva A.V., Chegus L.A. Abnormal uterine bleeding in women of reproductive age and premenopause. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2020; (8): 29-38. (in Russian)
38. Nooh A.M., Abdeldayem H.M., Girbash E.F., et al. Depo-Provera versus norethisterone acetate in management of endometrial hyperplasia without atypia. Reprod Sci. 2016; 23: 448-54.
39. Moradan S., Nikkhah N., Mirmohammadkhanai M. Comparing the administration of letrozole and megestrol acetate in the treatment of women with simple endometrial hyperplasia without atypia: a randomized clinical trial. Adv Ther. 2017; 34: 1211-20.
40. Moore E., Shafi M. Endometrial hyperplasia. Obstet Gynaecol Reprod Med. 2013; 23: 88-93.
41. Beavis A.L., Cheema S., Holschneider C.H., et al. Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk. Gynecol Oncol Rep. 2015; 13: 71-5.
42. Concin N., Matias-Guiu X., Vergote I., Cibula D., et al. ESGO/ ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiother Oncol. 2021; 154: 327-53. DOI: https://doi.org/10.1016/j.radonc.2020.11.018
43. Trimble C.L., Method M., Leitao M., et al. Management of endometrial precancers. Obstet Gynecol. 2012; 120: 1160-75.
44. Gallos I.D., Yap J., Rajkhowa M., et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2012; 207: 266.e1-12.
45. Simpson A.N., Feigenberg T., Clarke B.A., et al. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecol Oncol. 2014; 133: 229-33.
46. Orbo A., Arnes M., Vereide A.B., et al. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG. 2016; 123: 1512-9.
47. Park J.Y., Lee S.H., Seong S.J., et al. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertilitysparing management using progestin. Gynecol Oncol. 2013; 129: 7-11.
48. Gressel G.M., Parkash V., Pal L. Management options and fertilitypreserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer. Int J Gynaecol Obstet. 2015; 131: 234-9.